Howard Berman, PhD Independent Director Age: 52 Director Since: 2025 Class: III Committee Memberships Strategy and Public Policy Nominating and Corporate Governance Education University of Michigan, BS Weill Cornell Medical School, PhD, Neuroscience and Pharmacology Qualifications and Expertise Provided to Our Board Dr. Berman s experience cultivated through significant roles within major pharmaceutical companies including AbbVie, Eli Lilly, and Novartis focusing on clinical development and drug launches, and his experience as a public biotechnology company CEO and founder will provide the Board with key insights into pharmaceutical development and commercialization strategy. Dr. Berman s unique capacity to integrate deep scientific understanding with strong business and entrepreneurial acumen, will significantly enhance the Board s ability to strategically guide the Company and strengthen the Board s oversight of the Company s operational execution. Professional Experience Chairman (formerly Executive Chairman) and CEO of ReAlta Life Sciences, Inc., a clinical stage biopharmaceutical company focused on targeting neutrophils and central components of the complement system for the treatment of inflammatory disorders (2025 to present) Founder, Executive Chairman and CEO of Coya Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing multimodality Treg therapies for the treatment of neurodegenerative, autoimmune and metabolic diseases (2020-2026) Founder of Imaware Inc. , a digital health company that developed and commercializes remote blood biomarker testing and monitoring (2018-2024) Senior Medical Liaison roles at numerous pharmaceutical companies (2003-2020), including: o Abbvie Inc. : led engagement with key opinion leaders to advance oncology assets and contributed to development and multi-billion dollar launch of Venclexta and other products (2013-2020) o Eli Lilly and Co. : company s scientific point of contact with and key opinion leader for development and initiation of collaborations, clinical trials and managed key academic partnerships and contributed to multi-billion dollar launch of Alimta (2009-2013) o Novartis Pharmaceuticals Corporation : managed key opinion leader collaborations to support broad portfolio of CNS drugs targeting epilepsy, Parkinson s Disease, Alzheimer s Disease, MS, ADHD, and other neurological conditions and contributed to launch of Focalin-XR (2003-2006) Other Public Company Directorships (past five years): Coya Therapeutics, Inc. (Ticker: COYA), 2020-2026 Core Skills Drug Development / Scientific Experience Life Sciences / Healthcare Industry Business Development / Strategic Partnerships Finance & Audit M&A / Strategic Investments Senior Executive Role Corporate Governance